Vulnerability to Infections and Secondary Immunodeficiencies in Patients with Non-Hodgkin’s Lymphomas Starting Anti-CD20 Antibody-Containing Therapies

Compared to the period before receiving CD20CT, serum IgG levels and T-helper cells decreased and patients suffered from increased infection rates. Immune monitoring is only performed in a minority of patients.